Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Since the below press release put up last December, there is no any further news on the progress, the board should inform the PIs timely on the progress, if any of the planned options go ahead, judging the blood circulation related cardio-vascular disease sufferers huge numbers in China, this company will become profitable overnight and LT share holders will expect a dividend payment.
'The Company is working closely with By-Health Co., Ltd, a £5bn listed Chinese dietary supplement business, to support the planned launch of some Fruitflow based products in the Chinese market. The planned launch is progressing well with potential sales volumes remaining at a significant multiple of existing Fruitflow sales.
By-Health has made a significant investment in nine separate clinical studies in China, at its sole expense, in support of the Fruitflow based products which it plans to launch in China. The five studies which have been completed by By-Health showed excellent results in use for Fruitflow, and provide strong evidence for By-Health in its regulatory submissions for Fruitflow.
If a successful blue cap health claim is achieved for Fruitflow in China it would currently be expected to result in some significant recurring orders for Fruitflow, at a multiple of current total sales values.'
Not all studies will have been published and there is no direct link for all the info.
Here is some info (links) to look through if you are interested.
By-Health website Institute of Nutrition and Health
http://www.binh.cn/#/index3?id=2b1d9f2bbde14a8b9f34b425cb40515f
Studies.
Water-soluble tomato extract improves platelet function in subjects with metabolic syndrome: a randomized clinical trail
Date of Registration:2020-12-02
http://www.chictr.org.cn/showprojen.aspx?proj=64530
Effect of combination of Fruitflow and aspirin on platelet function and endothelial cells
Date of Registration:2020-07-13
http://www.chictr.org.cn/showprojen.aspx?proj=56370
Human intervention study on dietary intake of water-soluble tomato extract
Date of Registration:2017-10-10
http://www.chictr.org.cn/showprojen.aspx?proj=22104
Effect of water-soluble tomato extract on hypercholesterolemia
Date of Registration:2018-04-27
http://www.chictr.org.cn/showprojen.aspx?proj=27052
Investigation of the Anti-hypertensive Role of Specific Plant Extracts in Hypertenison Patients
Date of Registration:2018-05-04
http://www.chictr.org.cn/showprojen.aspx?proj=27048
Publications
The water-soluble tomato concentrate Fruitflow inhibits its activation, aggregation and thrombosis by regulating the platelet PI3K/Akt and MAPKs signaling pathways
http://www.cnki.com.cn/Article/CJFDTotal-ZSYK202002011.htm
Inhibitory effect of Fruitflow on platelet function: a randomized placebo-controlled trial in elderly subjects
https://www.researchsquare.com/article/rs-95541/v1
Fruitflow attenuates human platelet granule secretion through down-regulating Src/PLC?2/PKC signaling pathway
https://www.researchsquare.com/article/rs-17401/v1
Toxicological Evaluation of Edible Safety of Water-soluble Tomato Concentrate (Fruitflow?)
http://www.fx361.com/page/2019/1205/6076972.shtml
Effects of water-soluble tomato concentrate on platelet aggregation
https://www.wjtcm.net/article.asp?issn=2311-8571;year=2019;volume=5;issue=4;spage=260;epage=268;aulast=Zhan
Study on the Antioxidant and Auxiliary Effects of Water-soluble Tomato Concentrate in Lowering Blood Lipid
https://r.cnki.net/kcms/detail/detail.aspx?filename=SPAJ202013071&dbcode=CRJT_CJFD&dbname=CJFDAUTO&v=
Study on the anti-platelet aggregation effect of water-soluble tomato concentrate
http://cdmd.cnki.com.cn/Article/CDMD-84502-1019240650.htm
Patents
WO2020077747 - COMPOSITION FACILITATING LOWERING OF BLOOD PRESSURE AND DIETARY SUPPLEMENT
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020077747&_cid=P11-KJGTMR-22408-1
CN109380728 - COMPOSITION AND HEALTH-CARE FOOD WITH AUXILIARY BLOOD PRESSURE LOWERING EFFECT
https://patentscope.wipo.int/search/en/detail.jsf?docId=CN238963528&_cid=P11-KJGTMR-22408-1
Hi all , same old here then Lol !
Re "By-Health has made a significant investment in nine separate clinical studies in China"
BH make lots of money to them it was pennies and it is not a signal that they are about to launch a nationwide FF product , IMO . It's the CCCP that decide what is going to fly out there , it's all a huge gamble.
From By-Health Institute of Nutrition and Health website.
"Research progress
In recent years, the company has taken "Fruitflow® (water-soluble tomato concentrate)" as its main direction, focusing on the development of new functional products that help maintain cardiovascular health.
The project brought together domestic authoritative scientific research resources such as the Institute of Chinese Materia Medica of the Chinese Academy of Chinese Medical Sciences and the School of Public Health of Sun Yat-Sen University, and adopted By-Health ® Xinluo Su Tablets (the main functional ingredients are the same as those approved by EFSA, all are water-soluble tomato concentrates). Experimental samples, refer to domestic and foreign literature and methods approved and published by EFSA, and conducted in-depth investigations around related issues, and finally determined to establish a new function of "help maintain normal platelet aggregation and contribute to healthy blood flow". Animal function test evaluation of health food Methods and evaluation methods of the population test.
At present, this method has been repeatedly verified in Beijing Hospital, Peking University Third Hospital, Dongzhimen Hospital of Beijing University of Chinese Medicine, China Academy of Chinese Medical Sciences, Sun Yat-sen University and other domestic research institutions. The test results prove that the method has wide applicability, easy operation and detection. The results are reproducible. The project seeks safer antiplatelet substances to maintain normal platelet aggregation, reduces the risk factors for the occurrence and development of cardiovascular diseases, and makes an effective exploration for the research on new functions of health foods and the profound significance of maintaining public health."
https://www.binh.cn/aboutUs?id=713b66daab974fafab39d8b09002b2e3&title=%E5%85%B3%E4%BA%8E%E6%96%B0%E5%8A%9F%E8%83%BD%E7%A0%94%E7%A9%B6&navTitle=%E9%A6%96%E9%A1%B5%20%3E%20%E6%96%B0%E5%8A%9F%E8%83%BD%E7%A0%94%E7%A9%B6%20%3E%20%E5%85%B3%E4%BA%8E%E6%96%B0%E5%8A%9F%E8%83%BD%E7%A0%94%E7%A9%B6%20%3E%20%E8%AF%A6%E6%83%85&menuItemId=b04733902fc64eaa80a0b7e54e39a200
the company (By-Health) has taken "Fruitflow® (water-soluble tomato concentrate)" as its main direction, focusing on the development of new functional products that help maintain cardiovascular health.
Says it all really.
Hi gixer,
So it seems there is no conclusion. So what do you make of it?
IMO all By-Health is waiting on is the green light from SAMR.
100% Gixer. We will then very quickly be offered a buy out by them
Hi gixer,
Thanks for your thoughts. What does SAMR stands for? Is it the Chinese regulator?
state administration for market regulation
Could be on the money there , it could be explosive as a generous buy out would still be peanuts for BH. Thanks for research Gixer.
AKA CCCP , they all want their cut.
Is SAMR the regulator for Blue Hat? If so then I assume the other trials are still outstanding. If not, then aren't By-Health waiting on both SAMR and Blue Hat or are they alternative retail channels?
From the 2019 results
" The planned launch of a number of Fruitflow based products in the Chinese market, with potential volumes at a significant multiple of existing Fruitflow sales, is progressing well, with activities driven at present by the need to obtain ‘blue cap’ health claim status for Fruitflow as a dietary supplement with the State Administration for Market Regulation (SAMR), a new Chinese market regulator which has taken over the responsibilities of the former China Food and Drug Administration (CFDA). "
Just to add...
The studies are not only for Blue Cap.
This is from the interim results.
"The five completed studies showed excellent results in use for Fruitflow, and they provide strong evidence for
By-Health in its blue cap and other regulatory submissions to the SAMR for Fruitflow, supported by the
Company’s existing European Food Safety Authority (‘EFSA’) health claim for Fruitflow."
What these "other regulatory submissions" are is still unclear (at least to me) but I have a theory.
Thanks to you Gixer , I am feeling much better about PXS now.
It feels like this could be a really exciting 12 months ahead for PXS. It's been a long time coming, and the lack of news drags the life out of you sometimes, but there really could be good times ahead. I'm hoping we don't get taken over, at least until we've established what represents fair value if/when the By Health research comes good.
Gixer,
From the same interims it was stated that ByHealth were planning to undertake 9 separate studies (as part of the Blue Cap application process). It is really frustrating that the Company have not provided any further updates on progress since January. Have you been able to eek out any additional information on this?
I was impressed by the statement that you extracted from the ByHealth Website: "the company has taken "Fruitflow® (water-soluble tomato concentrate)" as its main direction, focusing on the development of new functional products that help maintain cardiovascular health." I presume that this was a translation from the original Chinese but it nevertheless shows a real drive by ByHealth in our direction.
I was also impressed by the abstract recently posted on the Provexis website, indicating a potential number of other uses for WSTE and possibly even indicative of use within mainstream medicine.
Like Krusty, I am feeling much more confident in this share than I have for a number of years - but, my god, it is a frustrating share to follow with its lack of updates.
PXS's exclusive manufacturing agreement with DSM is our security I imagine , have BH been allowed to make FF in China ? I forget.
DSM is our commercial partner, so everyone benefits if China comes good.
Slam01, "Have you been able to eek out any additional information on this?"
I will post anything of interest that i find on Blue Cap (or other) but tbh its just a waiting game.
Maybe something else By-health should look into . https://www.dailymail.co.uk/sciencetech/article-9749419/Aspirin-cut-risk-death-cancers-20-study-finds.html